| Trial ID: | L6714 |
| Source ID: | NCT00575471
|
| Associated Drug: |
Rivoglitazone Hcl
|
| Title: |
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Rivoglitazone HCl|DRUG: rivoglitazone HCl|DRUG: rivoglitazone HCl|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in HbA1c from baseline for rivoglitazone compared to placebo, 12 weeks | Secondary: Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to placebo, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Daiichi Sankyo Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
250
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-07
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2009-03-02
|
| Locations: |
Fukuoka, Japan|Osaka, Japan|Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00575471
|
